Cart
sales@molnova.com
EDO-S101
CAS No. 1236199-60-2
EDO-S101 ( EDO-S 101;Tinostamustine )
Catalog No. M10949 CAS No. 1236199-60-2
EDO-S101 (Tinostamustine)is a fusion molecule comprising of the alkylator bendamustine and the HDAC-inhibitor vorinostat.
Purity : >98% (HPLC)
COA
Datasheet
HNMR
HPLC
MSDS
Handing Instructions
| Size | Price / USD | Stock | Quantity |
| 2MG | 49 | In Stock |
|
| 5MG | 69 | In Stock |
|
| 10MG | 113 | In Stock |
|
| 25MG | 186 | In Stock |
|
| 50MG | 332 | In Stock |
|
| 100MG | Get Quote | In Stock |
|
| 200MG | Get Quote | In Stock |
|
| 500MG | Get Quote | In Stock |
|
| 1G | Get Quote | In Stock |
|
Biological Information
-
Product NameEDO-S101
-
NoteResearch use only, not for human use.
-
Brief DescriptionEDO-S101 (Tinostamustine)is a fusion molecule comprising of the alkylator bendamustine and the HDAC-inhibitor vorinostat.
-
DescriptionEDO-S101 (Tinostamustine)is a fusion molecule comprising of the alkylator bendamustine and the HDAC-inhibitor vorinostat; displays potent activity in vitro in MM cell lines (IC50=1.6-4.8 uM) and ex vivo in cells isolated from MM patients; shows activity in CB17-SCID murine plasmacytoma model and in de novo Vk*MYC mice, also is the only drug with single-agent activity in the multidrug resistant Vk12653 murine model.Blood Cancer Phase 1 Clinical
-
SynonymsEDO-S 101;Tinostamustine
-
PathwayCell Cycle/DNA Damage
-
TargetHDAC
-
RecptorHDAC1;HDAC2;HDAC3;HDAC6;HDAC8
-
Research AreaCancer
-
IndicationBlood cancer
Chemical Information
-
CAS Number1236199-60-2
-
Formula Weight415.36
-
Molecular FormulaC19H28Cl2N4O2
-
Purity>98% (HPLC)
-
SolubilityDMSO: ≥ 30 mg/mL
-
SMILESCN1C2=C(C=C(C=C2)N(CCCl)CCCl)N=C1CCCCCCC(=O)NO
-
Chemical Name1H-Benzimidazole-2-heptanamide, 5-[bis(2-chloroethyl)amino]-N-hydroxy-1-methyl-
Shipping & Storage Information
-
Storage(-20℃)
-
ShippingWith Ice Pack
-
Stability≥ 2 years
Reference
1. Mehrling T, et al. Anticancer Agents Med Chem. 2016;16(1):20-8.
2. López-Iglesias AA, et al. J Hematol Oncol. 2017 Jun 20;10(1):127.
3. Besse L, et al. Blood Cancer J. 2017 Jul 28;7(7):e589.
2. López-Iglesias AA, et al. J Hematol Oncol. 2017 Jun 20;10(1):127.
3. Besse L, et al. Blood Cancer J. 2017 Jul 28;7(7):e589.
molnova catalog
related products
-
Phenylethyl isothioc...
Phenylethyl isothiocyanate is an HDAC inhibitor. It potentially for the treatment of benign prostatic hypertrophy.
-
LAQ824
LAQ824 (Dacinostat) is a novel HDAC inhibitor with IC50 of 32 nM and is known to activate the p21 promoter.
-
Benzenebutyric acid
Benzenebutyric acid is an inhibitor of HDACand is an antineoplastic agent.
